---
schema_version: "secwatch.filing_event.v1"
accession: "0001630627-26-000010"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:47:39.001818+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Treace prelim Q1 rev $47.0-47.2M; FY26 guidance raised to $202-212M; CCO departs

## Summary
- Preliminary Q1 revenue expected $47.0-47.2M; cash $51.9M, up $3.5M from Dec 2025.
- Full-year 2026 revenue guidance updated to $202-212M vs prior $200-212M.
- Chief Commercial Officer Gaetano Guglielmino departed April 8; role not replaced.
- CCO to consult through Jan 2027; $36,667/month fee, COBRA, prorated bonus, equity vest.
- SVP Sales will now report directly to CEO John Treace.

## SEC filing metadata
- accession: 0001630627-26-000010
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000163062726000010/0001630627-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000163062726000010/tmci-20260408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001630627-26-000010
- JSON: https://secwatch.observer/filing/0001630627-26-000010.json
- Plain text: https://secwatch.observer/filing/0001630627-26-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.